Credit Suisse’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,283
| Closed | -$113K | – | 3152 |
|
|
2023
Q3 | $113K | Sell |
2,283
-132
| -5% | -$6.53K | ﹤0.01% | 3080 |
|
|
2023
Q2 | $189K | Buy |
2,415
+590
| +32% | +$46.1K | ﹤0.01% | 3085 |
|
|
2023
Q1 | $165K | Buy |
1,825
+208
| +13% | +$18.8K | ﹤0.01% | 3135 |
|
|
2022
Q4 | $191K | Buy |
1,617
+295
| +22% | +$34.8K | ﹤0.01% | 3182 |
|
|
2022
Q3 | $239K | Buy |
1,322
+225
| +21% | +$40.7K | ﹤0.01% | 3160 |
|
|
2022
Q2 | $98K | Buy |
1,097
+37
| +3% | +$3.31K | ﹤0.01% | 3519 |
|
|
2022
Q1 | $164K | Buy |
1,060
+72
| +7% | +$11.1K | ﹤0.01% | 3402 |
|
|
2021
Q4 | $293K | Sell |
988
-168
| -15% | -$49.8K | ﹤0.01% | 3301 |
|
|
2021
Q3 | $667K | Buy |
1,156
+361
| +45% | +$208K | ﹤0.01% | 2832 |
|
|
2021
Q2 | $361K | Buy |
795
+313
| +65% | +$142K | ﹤0.01% | 3190 |
|
|
2021
Q1 | $258K | Sell |
482
-640
| -57% | -$343K | ﹤0.01% | 3200 |
|
|
2020
Q4 | $991K | Buy |
+1,122
| New | +$991K | ﹤0.01% | 2584 |
|